Arcellx Acquired by Gilead Sciences | Healthcare M&A Deal

Gilead Sciences has completed the acquisition of Arcellx, a healthcare services other business in the United States. Arcellx develops cell-based therapies and supports commercialization planning for its lead investigational product anito-cel, positioning the company for a potential launch. Gilead Sciences acquisitions in healthcare M&A aim to expand its oncology and immunology pipeline through a platform acquisition centered on advanced therapeutics. The Gilead Sciences acquires Arcellx transaction is a strategic acquisition with undisclosed deal size, structured as a platform acquisition to accelerate growth ahead of anito-cel commercialization.